Elizabeth J. Baker

Elizabeth J. Baker

Auto-generated profile, based on publicly available information

Elizabeth J. Baker

Physicians Committee for Responsible Medicine (PCRM), Washington, DC 20016, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Drug Discovery Today
Verified
Journal Article
Open access
EBElizabeth J. Baker
Elizabeth J. Baker
NBNancy A. Beck
Nancy A. Beck
EBEllen L. Berg
Ellen L. Berg
HCHelene D. Clayton-Jeter
Helene D. Clayton-Jeter
PCP. Charukeshi Chandrasekera
P. Charukeshi Chandrasekera
KSKristie M. Sullivan
Kristie M. Sullivan
Nonclinical tests are considered crucial for understanding the safety of investigational medicines. However, the effective translation from nonclinical to human application is limited and must be improved. Drug development stakeholders are working to advance human-based in vitro and in silico methods that may be more predictive of human efficacy and safety in vivo because they enable scientists to model the direct interaction of drugs with human cells, tissues, and biological processes. Here, we recommend test-neutral regulations; increased funding for development and integration of human-based approaches; support for existing initiatives that advance human-based approaches; evaluation of new approaches using human data; establishment of guidelines for procuring human cells and tissues for research; and additional training and educational opportunities in human-based approaches.

31 December 2024 in Toxics
Verified
Journal Article
Open access
PDF file
SBSabina Burla
Sabina Burla
ACAline Chary
Aline Chary
TSTommaso Serchi
Tommaso Serchi
SCSébastien Cambier
Sébastien Cambier
KSKristie Sullivan
Kristie Sullivan
AGArno Christian Gutleb
Arno Christian Gutleb
In recent years, a global increase in allergy incidence following chemical exposure has been observed. While the process of skin sensitization is well characterized through the adverse outcome pathway (AOP) framework, the immunological mechanisms underlying respiratory sensitization remain less well understood. Respiratory sensitizers are classified as substances of very high concern (SVHC) under the European Union (EU) regulation for the registration, evaluation, authorization and restriction of chemicals (REACH), emphasizing the importance of evaluating respiratory tract sensitization as a critical hazard. However, the existing new approach methodologies (NAMs) for the identification of skin sensitizers lack the capacity to differentiate between skin and respiratory sensitizers. Thus, it is imperative to develop physiologically relevant test systems specifically tailored to assess respiratory sensitizers. This study aimed to evaluate the efficacy of ALIsens®, a three-dimensional (3D) in vitro alveolar model designed for the identification of respiratory sensitizers and to determine its ability to correctly identify sensitizers. In this study, we used a range of skin sensitizers and non-sensitizers to define the optimal exposure dose, identify biomarkers, and establish tentative thresholds for correct sensitizer classification. The results demonstrate that ALIsens® is a promising in vitro complex model that could successfully discriminate respiratory sensitizers from skin sensitizers and non-sensitizers. Furthermore, the thymic stromal lymphopoietin receptor (TSLPr) cell surface marker was confirmed as a reliable biomarker for predicting respiratory sensitization hazards.